Biotinylated Human TROP-2 Protein (C-Avi-6His)

Name: Biotinylated Human TROP-2 Protein (C-Avi-6His)
Brand: Beta LifeScience
SKU: BL-2540NP
Price: 679.0 USD
Availability: InStock

BL-2540NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Avi-tagged proteins, Biotinylated proteins, Featured biotinylated protein molecules, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Biotinylated Recombinant Human Tumor-associated Calcium Signal Transducer 2 is produced by our Mammalian expression system and the target gene encoding His27-Thr274 is expressed with a Avi, 6His tag at the N-terminus.
Accession	P09758
Synonym	Tumor-associated calcium signal transducer 2; Membrane component chromosome 1 surface marker 1; Cell surface glycoprotein Trop-2; TACSTD2; TROP2
Gene Background	Tumor associated calcium signal transducer 2 (TACSTD2, TROP-2) is a type I cell surface glycoprotein that is highly expressed on human carcinomas. It was originally identified as an antigen present on human gastrointestinal tumors and is the second of two members of this family. Human and mouse TROP-2 share 87% amino acid (aa) similarity. TROP-2 is capable of transducing an intracellular calcium signal and may play a role in tumor growth. It also has adhesive functions.
Molecular Mass	30.5 KDa
Apmol Mass	40-60 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Biologically active. Please contact us to obtain bioactivity data.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	May function as a growth factor receptor.
Subcellular Location	Membrane; Single-pass type I membrane protein.
Protein Families	EPCAM family
Database References	HGNC: 11530 OMIM: 137290 KEGG: hsa:4070 STRING: 9606.ENSP00000360269 UniGene: Hs.23582
Associated Diseases	Corneal dystrophy, gelatinous drop-like (GDLD)
Tissue Specificity	Placenta, pancreatic carcinoma cell lines.

Gene Functions References

The results suggest that TROP2 expression could be an effective prognostic biomarker for oral squamous cell carcinoma PMID: 30098828
TROP-2, SLP-2 and CD56 were effective diagnostic markers for PTC, especially when they were combined to use. PMID: 29951933
Trop2 has a potential role in the promotion of EMT in BC. PMID: 29901160
these results suggested that TROP2 may promote osteosarcoma cell proliferation and migration via PI3K/AKT signaling and may serve as a novel treatment target for osteosarcoma . PMID: 29845216
TACSTD2 downregulation is associated with hepatocellular carcinoma. PMID: 29538454
findings demonstrate that a membranous TROP-2 staining pattern is highly specific for PTC, which may serve as a potential diagnostic marker aiding in the accurate classification of morphologically equivocal thyroid follicular-patterned lesions PMID: 26862947
TROP2 promoted the proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT. PMID: 28423362
The results from clinical specimens showed that Trop2 expression correlated with MMP2 expression in primary thyroid cancer. The current study suggests that elevated expression of Trop2 may represent an important molecular hallmark that is biologically and clinically relevant to the progression of thyroid cancer. PMID: 28709407
these results suggest a differential role for TROP2 in different lung cancer subtypes PMID: 28404926
Results show that TROP2 expression is up-regulated in gastric tumor and its co-expression with AREG protein is associated with TNM stage, tumor size, lymph node metastases, and distant metastases. PMID: 28256068
Our findings indicate that the expression of Trop-2 is a stringent predictor of tumor response to AKT inhibitors. They also support the identification of target-activatory pathways, as efficient predictors of response in precision cancer therapy. PMID: 27022065
Findings suggest that high TROP2 expression identifies distinct cell sub-populations in androgen-sensitive and androgen-independent prostate tumors and that it may be a predictive biomarker for prostate cancer treatment response in androgen-sensitive tumors. PMID: 27283984
TROP2 may play a crucial role in COPD by affecting basal cells function and thus airway remodeling through increased basal cells hyperplasia PMID: 27887617
TROP2 was overexpressed specifically in the majority of epithelial ovarian cancer and may be a novel prognostic biomarker PMID: 27127000
we compared the diagnostic value of TROP-2 expression in distinguishing between benign and malignant thyroid lesions to those of HBME-1, CK19 and galectin-3 PMID: 28547974
TROP-2 membranous staining is a very sensitive and specific marker for the classic and tall cell variants of papillary thyroid carcinoma, and for papillary microcarcinomas , with high overall specificity for papillary thyroid carcinoma PMID: 27311870
The results suggested that trop2 facilitated neovascularization of non-small-cell lung cancer via activating ERK1/2 signaling pathway. PMID: 28345466
We identified a homozygous TACSTD2 missense mutation, c.551A>G, p.(Tyr184Cys), in the affected family members. Both parents were heterozygous for the mutation, and unaffected siblings were either heterozygous or homozygous wild-type for this allele. PMID: 27227392
Our results expand the mutational spectrum of TACSTD2 in patients with gelatinous drop-like corneal dystrophy (GDLD). PMID: 27149532
Trop2 expression was higher in GC tissues than in neighboring non-tumor tissues. Increased Trop2 protein levels in GC were associated with increased differentiation, tumor node metastasis stage, tumor size, lymph node metastasis, distant metastasis, and H. pylori infection. PMID: 26716416
Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. PMID: 26101915
TROP2 is epigenetically down-regulated and operates as a negative regulator of cell proliferation and migration in liver fluke-associated cholangiocarcinoma. PMID: 26626643
TROP-2 is specifically expressed in papillary thyroid carcinoma. PMID: 26481593
overexpression of TROP2 appears to be an independent predictor for poor clinical outcome in nasopharyngeal carcinoma PMID: 26617817
Lower GA733-2 expression in cancer tissues appeared to correlate with lymph node metastases (P < 0.05). GA733-1 gene expression was significantly higher in cancerous samples PMID: 26600538
TROP-2 can be used as well as HBME-1 in thyroid cytology to detect PTC. PMID: 25164548
Altogether, our data suggest that TROP2 plays an important role in promoting ADC and may represent a novel prognostic biomarker and therapeutic target for the disease. PMID: 26773504
TROP2 protein is expressed at high levels in the colon cancer tissues. PMID: 26059528
TACSTD2 protein, human is predicting lymph node metastases in OSCC, overall survival and disease-free survival. PMID: 24764155
The amino acid exchange resulting from 4461T[C does not appear to alter binding of HO-3, suggesting that treatment with catumaxomab can be offered to patients regardless of their TACSTD1-genotype. PMID: 26115884
These observations suggest that Trop2 serves an oncogenic role in LSCC and has potential as a therapeutic target PMID: 25779928
This study reveals that both EpCAM and Trop2 overexpression in pituitary adenomas correlate significantly with invasiveness and proliferation. Follow-up analysis shows that Trop2 is a predictive factor for recurrence/progression for PAs. PMID: 25550831
Trop2 loss triggers sensitivity to anti-ErbB3 antibodies, which results in reduced proliferation and tumorigenic growth of Trop2 negative head and neck squamous cell cancer cells. PMID: 25238142
studies have begun to identify the mechanisms underlying TROP2's functions, including regulated intramembrane proteolysis or specific interactions with integrin b1 and claudin proteins. PMID: 25523132
we demonstrate that the Trop-2 activation states are critical determinants of tumor progression and are powerful indicators of breast cancer patients survival. PMID: 24824621
Inhibition of Tacstd2 expression significantly inhibited chemotherapeutic reagent-induced apoptosis, and TACSTD2 regulated apoptotic gene expression through P63 containing the transactivation domain (TAp63). PMID: 24651436
Trop2 is important in proliferation and apoptosis regulation in CaSki cells, which may become a novel target for cervical cancer treatment. PMID: 24816726
Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PMID: 24086649
miR-125b-1 causes mitogen-activated protein kinase pathway dysfunction through regulation of TACSTD2 expression. PMID: 23416980
The results of this study suggested that the TROP2 correlated with malignancy, proliferation and angiogenesis in human gliomas PMID: 23397225
TROP2 gene expression can be used as an independent prognostic indicator for squamous cell carcinoma of the larynx. PMID: 22987366
Used the Sf9 cells to express the Trop2 ectodomain (Trop2EC) in two forms - wt glycosylated (gTrop2EC) and mutant non-glycosylated form (Trop2EC(Delta/N)). Recombinant protein was purified and structure studied. PMID: 23872121
Trop2 expression reflects a more malignant phenotype and may serve as an unfavorable prognostic factor for extranodal NK/T cell lymphoma, nasal type PMID: 23979406
The cells exhibited a low epithelial barrier function as well as decreased expression of tight-junction-related proteins claudin 1 and 7. PMID: 23868985
show that Trop-2 enhances directional prostate cancer cell migration, through modulation of Rac1 GTPase activity PMID: 23536555
Network hubs and interacting partners are co-expressed with Trop-2 in primary human tumours, supporting a role of this signalling network in cancer growth. PMID: 22562244
study characterized the expression of TACSTD2 in invasive ductal breast cancer(IDC) and adjacent non-malignant tissues; studies demonstrated that the high expression of TACSTD2 correlates with a poor prognosis in IDC PMID: 23031786
Our data support a model where above-baseline expression of wild-type Trop-2 is a key driver of human cancer growth. PMID: 22349828
High expression of TROP2 was associated with stage stage IIb colon cancer. PMID: 23055188
More than 90% of Gelatinous drop-like corneal dystrophy (GDLD) patients possessed the same haplotype with a Q118X mutation in TACSTD2. PMID: 23038033

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.